Using glucagon receptor antagonism to evaluate the physiological effects of extrapancreatic glucagon in totally pancreatectomised individuals: a randomised controlled trial
Authors' conclusion
We conclude that inhibition of the glucagon receptor using LY2409021 during OGTT in totally pancreatectomised individuals does not produce detectable effects on glucose, lipid or amino acid metabolism, ruling out metabolic effects of extrapancreatic glucagon.
Study context
- Population
- Totally pancreatectomised individuals and matched healthy controls9 pancreatectomised, 9 controls
- Comparison
- Glucagon receptor antagonist (GRA) LY2409021 300 mg vs placebo 10 h before OGTT
- Primary endpoint
- Difference in plasma glucose excursions between study days
Methodological detailscrossover, double-masked, placebo-controlled
- Crossover
- Double-masked
- Placebo-controlled
Primary result
As reported in the abstract
Glucose, lipids and amino acids in totally pancreatectomised individuals · 3 h OGTT
- Circulating glucose, lipids and amino acid levels unaffected by LY2409021 vs placebo
- Glucagon concentrations unchanged from fasting during OGTT on both study days
Further findings
Fasting plasma glucose in healthy controls · lower with LY2409021
P = 0.001
Fasting plasma glucose in healthy controls
- Augmented plasma amino acid concentrations with LY2409021 vs placebo in controls
Original publication
Using glucagon receptor antagonism to evaluate the physiological effects of extrapancreatic glucagon in totally pancreatectomised individuals: a randomised controlled trial. Diabetologia. Published 18 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →